Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myelomaHang Quach, H. Miles Prince, David Ritchie et al.|Leukemia|2009Cited by 586
A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphomaChan Y. Cheah, John F. Seymour, Stephen Opat et al.|British Journal of Cancer|2014Cited by 132
Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigenStefan Peinert, Dirk Hönemann, H. Miles Prince et al.|Gene Therapy|2010Cited by 118
Pretransplant <i>FLT3</i>-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcomeSun Loo, Andrew H. Wei, Richard Dillon et al.|Blood|2022Cited by 83
Twice Daily Dosing with the Highly Specific BTK Inhibitor, Bgb-3111, Achieves Complete and Continuous BTK Occupancy in Lymph Nodes, and Is Associated with Durable Responses in Patients (pts) with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)Constantine S. Tam, Andrew W. Roberts, Stephen Opat et al.|Blood|2016Cited by 37